Acticor Biotech lists on Euronext Growth Paris

Gilles Avenard, Chief Executive Officer, opens the trading day in Paris.

Acticor Biotech is specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms.

The group has one product in Phase II clinical development (Glenzocimab).